Success Metrics

Completion Rate
0%(0/3)
Active Trials
0(0%)
Terminated
3(100%)

Phase Distribution

Ph phase_2
1
33%
Ph phase_1
2
67%

Phase Distribution

2

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 2Efficacy & side effects
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 3 finished

Non-Completion Rate

100.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Terminated(3)

Detailed Status

Terminated3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (66.7%)
Phase 21 (33.3%)

Trials by Status

terminated3100%

Recent Activity

0 active trials
Showing 3 of 3
terminatedphase_1

Study Evaluating TRU-015 in B-Cell Non-Hodgkin's Lymphoma

NCT00521638
terminatedphase_2

Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis

NCT00634933
terminatedphase_1

Study of TRU-015 in Subjects With Membranous Nephropathy Secondary to Systemic Lupus Erythematosus

NCT00479622

Clinical Trials (3)

Showing 3 of 3 trials
NCT00521638Phase 1

Study Evaluating TRU-015 in B-Cell Non-Hodgkin's Lymphoma

Terminated
NCT00634933Phase 2

Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis

Terminated
NCT00479622Phase 1

Study of TRU-015 in Subjects With Membranous Nephropathy Secondary to Systemic Lupus Erythematosus

Terminated

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3